|
Gene: FBXO21 |
Gene summary for FBXO21 |
Gene summary. |
Gene information | Species | Human | Gene symbol | FBXO21 | Gene ID | 23014 |
Gene name | F-box protein 21 | |
Gene Alias | FBX21 | |
Cytomap | 12q24.22 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A0A024RBL8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23014 | FBXO21 | P19T-E | Human | Esophagus | ESCC | 2.18e-02 | 3.77e-01 | 0.1662 |
23014 | FBXO21 | P20T-E | Human | Esophagus | ESCC | 1.91e-19 | 5.26e-01 | 0.1124 |
23014 | FBXO21 | P21T-E | Human | Esophagus | ESCC | 1.12e-30 | 5.99e-01 | 0.1617 |
23014 | FBXO21 | P22T-E | Human | Esophagus | ESCC | 1.68e-21 | 4.28e-01 | 0.1236 |
23014 | FBXO21 | P23T-E | Human | Esophagus | ESCC | 1.87e-26 | 4.74e-01 | 0.108 |
23014 | FBXO21 | P24T-E | Human | Esophagus | ESCC | 5.43e-13 | 2.28e-01 | 0.1287 |
23014 | FBXO21 | P26T-E | Human | Esophagus | ESCC | 4.56e-43 | 7.73e-01 | 0.1276 |
23014 | FBXO21 | P27T-E | Human | Esophagus | ESCC | 5.22e-46 | 9.50e-01 | 0.1055 |
23014 | FBXO21 | P28T-E | Human | Esophagus | ESCC | 3.22e-22 | 5.16e-01 | 0.1149 |
23014 | FBXO21 | P30T-E | Human | Esophagus | ESCC | 2.74e-24 | 1.08e+00 | 0.137 |
23014 | FBXO21 | P31T-E | Human | Esophagus | ESCC | 9.03e-25 | 4.80e-01 | 0.1251 |
23014 | FBXO21 | P32T-E | Human | Esophagus | ESCC | 8.23e-11 | 2.75e-01 | 0.1666 |
23014 | FBXO21 | P36T-E | Human | Esophagus | ESCC | 3.61e-17 | 4.87e-01 | 0.1187 |
23014 | FBXO21 | P37T-E | Human | Esophagus | ESCC | 3.43e-18 | 4.04e-01 | 0.1371 |
23014 | FBXO21 | P38T-E | Human | Esophagus | ESCC | 9.11e-04 | 8.92e-02 | 0.127 |
23014 | FBXO21 | P39T-E | Human | Esophagus | ESCC | 1.52e-16 | 2.72e-01 | 0.0894 |
23014 | FBXO21 | P40T-E | Human | Esophagus | ESCC | 1.75e-16 | 3.03e-01 | 0.109 |
23014 | FBXO21 | P42T-E | Human | Esophagus | ESCC | 6.97e-14 | 4.83e-01 | 0.1175 |
23014 | FBXO21 | P44T-E | Human | Esophagus | ESCC | 3.30e-09 | 2.87e-01 | 0.1096 |
23014 | FBXO21 | P47T-E | Human | Esophagus | ESCC | 2.14e-16 | 3.12e-01 | 0.1067 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FBXO21 | SNV | Missense_Mutation | novel | c.886N>T | p.Arg296Cys | p.R296C | O94952 | protein_coding | deleterious(0) | possibly_damaging(0.88) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FBXO21 | SNV | Missense_Mutation | c.389N>A | p.Gly130Asp | p.G130D | O94952 | protein_coding | deleterious(0.01) | possibly_damaging(0.792) | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FBXO21 | SNV | Missense_Mutation | c.938G>T | p.Arg313Leu | p.R313L | O94952 | protein_coding | deleterious(0.01) | possibly_damaging(0.859) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FBXO21 | SNV | Missense_Mutation | c.1163N>C | p.Met388Thr | p.M388T | O94952 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-AO-A0J6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
FBXO21 | SNV | Missense_Mutation | c.1870N>A | p.Glu624Lys | p.E624K | O94952 | protein_coding | tolerated_low_confidence(0.13) | benign(0) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
FBXO21 | SNV | Missense_Mutation | c.1438N>C | p.Glu480Gln | p.E480Q | O94952 | protein_coding | tolerated(0.52) | benign(0.07) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FBXO21 | insertion | Frame_Shift_Ins | novel | c.432_433insT | p.Glu145Ter | p.E145* | O94952 | protein_coding | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
FBXO21 | deletion | Frame_Shift_Del | novel | c.598_626delNNNNNNNNNNNNNNNNNNNNNNNNNNNNN | p.Val200LeufsTer13 | p.V200Lfs*13 | O94952 | protein_coding | TCGA-AN-A049-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
FBXO21 | insertion | Nonsense_Mutation | novel | c.1161_1162insTTTTGACACTGTTTCACTTGAATTTTCTC | p.Met388PhefsTer2 | p.M388Ffs*2 | O94952 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
FBXO21 | SNV | Missense_Mutation | novel | c.1477N>T | p.Arg493Cys | p.R493C | O94952 | protein_coding | deleterious(0) | possibly_damaging(0.719) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |